In the BioHarmony Drug Report Database

"Preview" Icon

Fremanezumab

Ajovy (fremanezumab) is an antibody pharmaceutical. Fremanezumab was first approved as Ajovy on 2018-09-14. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.

 

Trade Name

 

Ajovy
 

Common Name

 

fremanezumab
 

ChEMBL ID

 

CHEMBL4297756
 

Indication

 

migraine disorders
 

Drug Class

 

Monoclonal antibodies: humanized, neural indications

Image (chem structure or protein)

Fremanezumab structure rendering